NAFLD, MAFLD and obesity: brothers in arms?

被引：0
作者：
Mariana Verdelho Machado
Helena Cortez-Pinto
机构：
[1] Universidade de Lisboa,Clínica Universitária de Gastrenterologia, Faculdade de Medicina
[2] Hospital de Vila Franca de Xira,Gastroenterology Department
来源：
Nature Reviews Gastroenterology & Hepatology | 2023年 / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
2022 was a proficuous year in both the nonalcoholic fatty liver disease (NAFLD) and obesity fields. Pharmacological treatment for obesity and NAFLD is moving forward, with the possibility of replacing bariatric surgery, artificial intelligence might help us access the histological effects of new drugs, and there were advances in personalized hepatocellular carcinoma screening in patients with NAFLD.
引用
收藏
页码：67 / 68
页数：1
相关论文
共 15 条
[1]  
Henry L(2022)Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world Aliment. Pharmacol. Ther. 56 942-956
[2]  
Paik J(2021)Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: histological perspective Clin. Mol. Hepatol. 27 44-57
[3]  
Younossi ZM(2022)Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH J. Hepatol. 77 1399-1409
[4]  
Soon G(2017)Treatment of NAFLD with diet, physical activity and exercise J. Hepatol. 67 829-846
[5]  
Wee A(2022)Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Lancet Diabetes Endocrinol. 10 393-406
[6]  
Naoumov NV(2022)Tirzepatide once weekly for the treatment of obesity N. Engl. J. Med. 387 205-216
[7]  
Romero-Gómez M(2020)Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes Diabetes Care 43 1352-1355
[8]  
Zelber-Sagi S(2022)Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression Clin. Gastroenterol. Hepatol. 20 283-292
[9]  
Trenell M(2021)Epidemiology and risk-stratification of NAFLD-associated HCC J. Hepatol. 75 1476-1484
[10]  
Gastaldelli A(2022)Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease Sci. Transl Med. 14 eabo4474-undefined
12